Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX
Tweet Send to a FriendGet Alerts FRX Hot Sheet
Price: $38.53 -0.44%
Rating Summary:
9 Buy, 9 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
9 Buy, 9 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade FRX Now!
Barclays on U.S. Specialty Pharmaceuticals: Model Updates
Analyst, Douglas D. Tsao, said, "We are updating models for FRX, MRX, WCRX, and PCRX in order to tie up some loose ends from C1Q results.
On Forest Labs (NYSE: FRX): We are tweaking our FY13 estimates, with our EPS estimate increasing to $0.95 from previous $0.86.
Medicis Pharmaceutical (NYSE: MRX): Our 2012 cash-adjusted EPS estimate moves to $2.68 from previous $2.58, with higher EPS driven by slightly higher revenues and lower spend, partially offset by slightly higher tax rate.
Pacira Pharmaceuticals (Nasdaq: PCRX): Our 2012 loss/share increases to ($1.59) from previous ($1.19), driven by slightly higher COGS, SG&A and sharecount, partially offset by slightly lower R&D.
Warner Chilcott (Nasdaq: WCRX): Our estimate moves to $3.43 from previous $3.51, largely driven by higher SG&A spend, partially offset by slightly higher revenues. (FY13 lowered from $3.57 to $3.43)
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Douglas D. Tsao, said, "We are updating models for FRX, MRX, WCRX, and PCRX in order to tie up some loose ends from C1Q results.
On Forest Labs (NYSE: FRX): We are tweaking our FY13 estimates, with our EPS estimate increasing to $0.95 from previous $0.86.
Medicis Pharmaceutical (NYSE: MRX): Our 2012 cash-adjusted EPS estimate moves to $2.68 from previous $2.58, with higher EPS driven by slightly higher revenues and lower spend, partially offset by slightly higher tax rate.
Pacira Pharmaceuticals (Nasdaq: PCRX): Our 2012 loss/share increases to ($1.59) from previous ($1.19), driven by slightly higher COGS, SG&A and sharecount, partially offset by slightly lower R&D.
Warner Chilcott (Nasdaq: WCRX): Our estimate moves to $3.43 from previous $3.51, largely driven by higher SG&A spend, partially offset by slightly higher revenues. (FY13 lowered from $3.57 to $3.43)
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
- UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
